Physician profile
Page Yin
NPI 1174978126
$3,031.80
in general payments reported to CMS, 2019-2025
15 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.90 · 2021: $175 · 2022: $85.02 · 2023: $729 · 2024: $670 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,625 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.76 |
| Education | $126.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $689.50 | 2023-2025 | Vraylar |
| Alkermes, INC. | $337.96 | 2020-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $317.88 | 2021-2023 | Ingrezza |
| Axsome Therapeutics, INC. | $309.27 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $290.60 | 2025 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $232.71 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $183.35 | 2023-2025 | Rexulti |
| Madrigal Pharmaceuticals | $129.63 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $115.46 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $110.10 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Mycite |
| Takeda Pharmaceuticals U.S.A., INC. | $80.30 | 2022-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.17 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $23.55 | 2025 | Fanapt |
| Almatica Pharma LLC | $19.32 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Page Yin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.